Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
Quick Takeaways Why It Matters? Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category. If LOY-002 secures conditional and then full approval, it could...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
